This initiative aims to increase access to essential medicines for people in developing countries, by increasing transparency and accountability in medicines procurement and supply chains to tackle inefficiency, corruption and fraud.

The Korean Pact for Anti-Corruption and Transparency (K-PACT) is a social pledge undertaken by actors at national level in the public and private sectors to establish corruption monitoring systems and to strengthen corporate ethics and social responsibility.

K-PACT is a national alliance made up of representatives from civil society, the public, private, and political sectors, committed to promoting and improving transparency in Korean society. Among the commitments made, this alliance has agreed to:

The Business Ethics Initiative seeks to promote anti-corruption and ethical business principles in Indonesia. Between 1999 and 2012, the Initiative:

• conducted 44 workshops on "Managing Ethical Dilemma for Facilitating Payment" and "Building Collective Action for Anti-Corruption";
• conducted 11 workshops on “Developing Business Codes of Conduct for SMEs” in 7 provinces with almost 400 SMEs;
• issued Guidelines for SMEs to develop Business Codes of Conduct (CoC);
• published four books on Business Ethics and CoC issues.

The Extractive Industries Transparency Initiative (EITI) is a global coalition of governments, companies and civil society working together to improve openness and accountable management of revenues from natural resources.

The EITI came about in an environment of increasing pressure from civil society organisations in the late 1990s for transparency in the payments and revenues stemming from the extractive industry. In 2003, the 12 EITI Principles, focusing on the need for transparent management of natural resources, were created. Goals:

This initiative, launched by the Russian business community, seeks to prevent and combat corruption by stating the corporate consensus against it, and setting forth measures to address corruption within and between companies, as well as between companies and government. The provisions of the charter apply to both the relations inside the business community and those between the business community and public authorities.

The China Business Leaders Forum (CBLF) is a joint initiative of the International Business Leaders Forum (IBLF) and Renmin University of China. The goals of the initiative are to:

1. Promote business practices that will ensure the sustainable social and economic development of China. A Business Integrity Handbook has been developed as a way to do this.
2. Promote good governance and encourage transparency, as well as shape new business leadership to help business leaders in China to better confront challenges in the global market.

The National Anti-Corruption Forum (NACF) was established in 2001 to combat and prevent corruption, build integrity and raise awareness.

The NACF is comprised of three sectors: 

• civil society 
• business
• government.

Each sector is represented by ten members nominated by their respective constituencies. The business sector is represented by 10 delegates from the Business Unity South Africa (BUSA).

The World Economic Forum Partnering Against Corruption Initiative (PACI) is a global, multi-industry, multi-stakeholder anti-corruption initiative set up to raise business standards and to contribute to a competitive, transparent, accountable and ethical business society. The goals are to:

This initiative was created by the International Business Leaders Forum (IBLF) and brings together business, government and not-for-profit organizations to improve public procurement processes. The goals of this initiative are: 

• clarify tender procedures, making them more transparent;
• build the confidence of the business community that tenders are being conducted in a fair and even-handed way;
• develop anti-corruption mechanisms in public procurement.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Code of Practice was first created in 1981 and is part of a decades-long commitment to promoting ethical practices in the pharmaceutical industry. The goal is to ensure that practices in the pharmaceutical industry are governed by ethical standards in line with societal expectations.

The Code has been revised six times since its inception. The current IFPMA Code of Practice came into effect on 1st January 2019, with the following changes compared to previous versions: